BridgeBio is substantially advanced its course of a new solution for ATTR-CM, leveraging the compound. Preliminary trial data indicates potential improvements for patients affected by this serious condition. This focus https://bridgebio304595.blogsvila.com/42464558/bridgebio-advances-cardiac-amyloidosis-therapy-with-the-drug